Sarepta Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-713.4M | $235.2M | $-536.0M | $-703.5M | $-418.8M | $-554.1M | $-715.1M | $-361.9M |
| Depreciation & Amortization | $44.5M | $37.7M | $44.4M | $41.9M | $38.0M | $26.9M | $24.5M | $12.2M |
| Depreciation | $51.4M | $42.7M | $42.5M | $40.0M | $36.6M | $25.2M | $22.8M | $10.2M |
| Amortization | $2.6M | $2.4M | $1.6M | $714.0K | $706.0K | $662.0K | $849.0K | $865.0K |
| Stock-Based Compensation | $123.4M | $184.3M | $182.5M | $233.0M | $113.9M | $108.1M | $78.6M | $50.1M |
| Net Cash from Operating Activities | $-205.5M | $-205.8M | $-501.0M | $-325.3M | $-443.2M | $107.5M | $-456.5M | $-388.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $102.0M | $137.0M | $76.1M | $30.8M | $38.5M | $82.2M | $59.6M | $61.2M |
| Business Acquisitions | — | — | — | — | — | — | $172.6M | — |
| Net Cash from Investing Activities | $69.6M | $755.6M | $-165.8M | $-1.05B | $495.4M | $-121.7M | $286.7M | $-370.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $25.0M | $0 | $0 | — | — | — | — | — |
| Net Cash from Financing Activities | $-168.3M | $124.8M | $125.0M | $232.5M | $561.6M | $682.3M | $642.6M | $530.2M |
| Net Change in Cash | $-304.2M | $674.6M | $-541.8M | $-1.14B | $613.8M | $668.1M | $472.8M | $-229.0M |
| Free Cash Flow | $-307.5M | $-342.7M | $-577.1M | $-356.2M | $-481.7M | $25.3M | $-516.1M | $-449.8M |